Ophthalmic compositions for treating ocular hypertension

摘要

Combinations of a prostaglandin, prostaglandin derivative, a hypotensive lipid derived from a prostaglandin or prostaglandin derivative or an ophthalmologically acceptable salt thereof, a beta -adrenergic antagonist or an ophthalmologically acceptable salt thereof and a topical carbonic anhydrase inhibitor or an ophthalmologically acceptable salt thereof are particularly useful in the treatment of ocular hypertension and glaucoma. The combinations are characterized by an improved effect and reduced side-effects.